Biomimetic Innovations

Biomimetic Innovations Ltd. is a medical device company focused on commercializing OsStic®, a synthetic biomaterial technology for skeletal and soft tissue repair. The company was established in 2020 as a result of a decade-long collaboration between two Irish-based firms, GP Bio Ltd. and PBC Biomed Ltd., both of which possess extensive expertise in biomaterials and bone repair. Key figures associated with the company's origins include Philip Procter, CEO of GPBio and co-founder of Biomimetic Innovations, Paul Burke, a co-founder and Managing Partner of PBC Biomed, and Dr. Gerard Insley, Chief Scientific Officer at PBC Biomed. Procter's journey began decades ago, driven by a mission to solve trauma hardware failure, leading him to explore natural adhesives and eventually partner with Dr. Insley and Professor Håkan Engqvist at the University of Uppsala, Sweden, to develop the OsStic® technology.

The company's core product, OsStic®, is an injectable, structural bio-adhesive designed for the reduction, provisional fixation, or void filling of peri-articular fractures and defects. It aims to enhance structural stability in situations where standard fixation methods like metal hardware are insufficient, particularly in complex fractures or poor-quality bone. The technology is inspired by nature, specifically the adhesive properties of phosphoserine, an amino acid used by sea creatures like mussels to stick to surfaces underwater. OsStic® is composed of simple ingredients: water, calcium, and phosphoserine. This biomimetic mechanism is intended to work with the body's natural healing process, eventually being remodeled and replaced by new bone tissue. The product's primary market includes trauma, spinal, and dental clinicians. In a significant milestone, the U.S. Food and Drug Administration (FDA) granted OsStic® a 'Breakthrough Device' designation in late 2023, a move set to accelerate its development, assessment, and review process.

Biomimetic Innovations operates as an affiliate of PBC Biomed, leveraging its parent company's ISO-certified facilities and infrastructure for design, development, and manufacturing. This relationship provides a clear pathway from research and development to commercialization. The business model appears to be centered on the development and subsequent sale of the OsStic® technology to the global orthopedic and surgical markets. An exclusive license and distribution agreement with Sanara MedTech Inc. for the U.S. market underscores this strategy, aiming to leverage Sanara's sales network to bring the product to surgeons and patients. Headquartered in Shannon, Ireland, the company has a global presence with offices in Chamonix, France, and Memphis, Tennessee, positioning it to serve both European and American markets.

Keywords: OsStic, bone adhesive, bio-adhesive, biomimetic technology, skeletal repair, soft tissue repair, bone void filler, trauma surgery, orthopedic devices, medical devices, PBC Biomed, GP Bio, Philip Procter, Paul Burke, Gerard Insley, injectable biomaterial, fracture treatment, provisional fixation, structural stability, phosphoserine, FDA Breakthrough Device, orthobiologics, bone regeneration, medical innovation